2B30 Stock Overview A biopharmaceutical company, engages in developing and commercializing therapies in Illinois. More details
Rewards Risk Analysis See All Risk Checks Capture your thoughts, links and company narrative
Xeris Biopharma Holdings, Inc. Competitors Price History & Performance
Summary of share price highs, lows and changes for Xeris Biopharma Holdings Historical stock prices Current Share Price US$3.47 52 Week High US$3.47 52 Week Low US$1.58 Beta 1.23 1 Month Change 4.39% 3 Month Change 20.32% 1 Year Change 48.29% 3 Year Change 91.71% 5 Year Change n/a Change since IPO 92.78%
Recent News & Updates
Xeris Biopharma Holdings, Inc. Raises Earnings Guidance for the Full Year 2024 Jan 11
Xeris Biopharma Holdings, Inc. to Report Fiscal Year 2024 Results on Mar 06, 2025 Jan 10
Third quarter 2024 earnings released: US$0.11 loss per share (vs US$0.088 loss in 3Q 2023) Nov 10
Xeris Biopharma Holdings, Inc. Raises Earnings Guidance for the Full Year 2024 Nov 08
Xeris Biopharma Holdings, Inc. to Report Q3, 2024 Results on Nov 08, 2024 Oct 31
Second quarter 2024 earnings released: US$0.10 loss per share (vs US$0.14 loss in 2Q 2023) Aug 09 See more updates
Xeris Biopharma Holdings, Inc. Raises Earnings Guidance for the Full Year 2024 Jan 11
Xeris Biopharma Holdings, Inc. to Report Fiscal Year 2024 Results on Mar 06, 2025 Jan 10
Third quarter 2024 earnings released: US$0.11 loss per share (vs US$0.088 loss in 3Q 2023) Nov 10
Xeris Biopharma Holdings, Inc. Raises Earnings Guidance for the Full Year 2024 Nov 08
Xeris Biopharma Holdings, Inc. to Report Q3, 2024 Results on Nov 08, 2024 Oct 31
Second quarter 2024 earnings released: US$0.10 loss per share (vs US$0.14 loss in 2Q 2023) Aug 09
Xeris Biopharma Holdings, Inc. Revises Earnings Guidance for the Full Year 2024 Aug 08
Xeris Biopharma Holdings, Inc. to Report Q2, 2024 Results on Aug 08, 2024 Jul 25 Xeris Biopharma Holdings, Inc. Announces CEO Changes
Xeris Biopharma Announces Positive Topline Phase 2 Clinical Data of Its Investigational XeriSol-Formulated Once-Weekly Subcutaneous (SC) Levothyroxine (XP-8121) May 31
Xeris Biopharma Holdings, Inc. Provides Revenue Guidance for the Full Year 2024 May 10
First quarter 2024 earnings released: US$0.14 loss per share (vs US$0.12 loss in 1Q 2023) May 09
Xeris Biopharma Holdings, Inc. to Report Q1, 2024 Results on May 09, 2024 May 03
Xeris Biopharma Holdings, Inc., Annual General Meeting, Jun 05, 2024 Apr 24
Full year 2023 earnings released: US$0.45 loss per share (vs US$0.70 loss in FY 2022) Mar 07
Xeris Biopharma Holdings, Inc. Provides Earnings Guidance for the Year 2024 Mar 06
Xeris Biopharma Holdings, Inc. to Report Q4, 2023 Results on Mar 06, 2024 Jan 05
Forecast to breakeven in 2026 Dec 31
Third quarter 2023 earnings released: US$0.088 loss per share (vs US$0.16 loss in 3Q 2022) Nov 11
Xeris Biopharma Holdings, Inc. Revises Revenue Guidance for the Full Year 2023 Nov 10
New major risk - Financial position Aug 09
Second quarter 2023 earnings released: US$0.14 loss per share (vs US$0.19 loss in 2Q 2022) Aug 09
Xeris Biopharma Holdings, Inc. Provides Revenue Guidance for the Full Year 2023 Aug 09
Xeris Biopharma Holdings, Inc. to Report Q2, 2023 Results on Aug 08, 2023 Aug 03
Xeris Biopharma Holdings, Inc. Announces First Participant Dosed in a Phase 2 Clinical Study of Its Investigational Subcutaneous (SC) Levothyroxine (XP-8121) in Patients With Hypothyroidism Jun 22
Forecast to breakeven in 2025 May 10
Xeris Biopharma Holdings, Inc. Affirms Earnings Guidance for 2023 May 10
First quarter 2023 earnings released: US$0.12 loss per share (vs US$0.25 loss in 1Q 2022) May 09
Full year 2022 earnings released: US$0.70 loss per share (vs US$1.55 loss in FY 2021) Mar 09
Xeris Biopharma Holdings, Inc. Updates Product Revenue Guidance for the Full Year 2022 Jan 06
Xeris Biopharma Announces Plans for a Phase II Dose-Finding Study for Its Investigational Subcutaneous (SC) Levothyroxine (XP-8121) as Replacement Therapy for Hypothyroidism Dec 16
High number of new and inexperienced directors Nov 16
Third quarter 2022 earnings released: US$0.16 loss per share (vs US$0.39 loss in 3Q 2021) Nov 10
Xeris Biopharma Holdings, Inc. Provides Product Revenue Guidance for the Full Year 2022 Nov 10
Xeris Biopharma Holdings, Inc. to Report Q3, 2022 Results on Nov 09, 2022 Nov 03
Xeris Biopharma Holdings, Inc. Announces Results of the Extended Evaluation of Recorlev (Levoketoconazole) from the Phase 3 Sonics Study Published in the European Journal of Endocrinology Nov 02
Second quarter 2022 earnings released: US$0.19 loss per share (vs US$0.41 loss in 2Q 2021) Aug 11
Xeris Biopharma Holdings, Inc. Reaffirms Revenue for the Full Year 2022 Aug 11
Xeris Biopharma Holdings, Inc. to Report Q2, 2022 Results on Aug 10, 2022 Aug 04
Arecor Therapeutics plc (AIM:AREC) agreed to acquire Tetris Pharma Limited from Xeris Biopharma Holdings, Inc. (NasdaqGS:XERS). Aug 02
Chairman & CEO recently bought €135k worth of stock May 14
First quarter 2022 earnings released: US$0.25 loss per share (vs US$0.30 loss in 1Q 2021) May 13
Xeris Announces Full Results from the Logics Study of Recorlev® and Presentation of New Burden of Illness in Cushing’s Syndrome Data At AACE Annual Meeting May 12-14 May 13
Xeris Biopharma Holdings, Inc. Affirms Revenue Guidance for the Year 2022 May 12
Xeris Biopharma Holdings, Inc. to Report Q1, 2022 Results on May 11, 2022 May 05
Less than half of directors are independent Apr 27
No longer forecast to breakeven Mar 15
Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat Mar 12
Xeris Biopharma Holdings, Inc. to Report Q4, 2021 Results on Mar 10, 2022 Mar 06
Xeris Biopharma Holdings, Inc. Announces Recorlev Is Now Commercially Available for the Treatment of Endogenous Hypercortisolemia in Adult Patients with Cushing’S Syndrome Feb 01
Xeris Biopharma Holdings, Inc. announced that it expects to receive $30 million in funding from Armistice Capital LLC Jan 04
Forecast to breakeven in 2024 Jan 01
Xeris Biopharma Announces U.S. FDA Approval of Recorlev (levoketoconazole) for the Treatment of Endogenous Hypercortisolemia in Adult Patients With Cushing’s Syndrome Dec 31
Xeris Biopharma Holdings, Inc Announces the Availability of Ogluo® in the UK Through Its Commercialization Partner, Tetris Pharma Dec 17
Chairman & CEO recently bought €363k worth of stock Nov 15
Third quarter 2021 earnings released: US$0.39 loss per share (vs US$0.35 loss in 3Q 2020) Nov 11
Less than half of directors are independent Oct 15 Shareholder Returns 2B30 DE Pharmaceuticals DE Market 7D 8.4% 1.5% 1.9% 1Y 48.3% -7.6% 15.1%
See full shareholder returns
Return vs Market: 2B30 exceeded the German Market which returned 15.1% over the past year.
Price Volatility Is 2B30's price volatile compared to industry and market? 2B30 volatility 2B30 Average Weekly Movement 6.1% Pharmaceuticals Industry Average Movement 5.3% Market Average Movement 4.8% 10% most volatile stocks in DE Market 11.3% 10% least volatile stocks in DE Market 2.4%
Stable Share Price: 2B30 has not had significant price volatility in the past 3 months compared to the German market.
Volatility Over Time: 2B30's weekly volatility (6%) has been stable over the past year.
About the Company Xeris Biopharma Holdings, Inc., a biopharmaceutical company, engages in developing and commercializing therapies in Illinois. The company offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing’s syndrome. It is also developing XP-8121, a once-weekly subcutaneous injection of levothyroxine that is in phase I clinical trial for the treatment of hypothyroidism; and non-aqueous XeriSol and XeriJect technologies for various therapies.
Show more Xeris Biopharma Holdings, Inc. Fundamentals Summary How do Xeris Biopharma Holdings's earnings and revenue compare to its market cap? 2B30 fundamental statistics Market cap €512.00m Earnings (TTM ) -€60.89m Revenue (TTM ) €180.75m
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) 2B30 income statement (TTM ) Revenue US$187.36m Cost of Revenue US$34.92m Gross Profit US$152.44m Other Expenses US$215.55m Earnings -US$63.11m
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
Mar 06, 2025
Earnings per share (EPS) -0.42 Gross Margin 81.36% Net Profit Margin -33.69% Debt/Equity Ratio -816.6%
How did 2B30 perform over the long term?
See historical performance and comparison
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2025/02/02 13:09 End of Day Share Price 2025/01/31 00:00 Earnings 2024/09/30 Annual Earnings 2023/12/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources Xeris Biopharma Holdings, Inc. is covered by 11 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution Chase Knickerbocker Craig-Hallum Capital Group LLC Robin Garner Kalley Craig-Hallum Capital Group LLC Oren Livnat H.C. Wainwright & Co.
Show 8 more analysts 